[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. 68(6): 394-424.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019. 69(1): 7-34.
[3] Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 2019. 322(8): 764-774.
[4] Villalobos P, Wistuba II. Lung Cancer Biomarkers. Hematol Oncol Clin North Am. 2017. 31(1): 13-29.
[5] Zou Y, Wang L, Zhao C, et al. CEA, SCC and NSE levels in exhaled breath condensate--possible markers for early detection of lung cancer. J Breath Res. 2013. 7(4): 047101.
[6] Li J, Chen P, Mao CM, Tang XP, Zhu LR. Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer. Asia Pac J Clin Oncol. 2014. 10(2): 141-8.
[7] Buil-Bruna N, López-Picazo JM, Moreno-Jiménez M, Martín-Algarra S, Ribba B, Trocóniz IF. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients. AAPS J. 2014. 16(3): 609-19.
[8] Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 2001. 31(2-3): 221-31.
[9] Yu D, Du K, Liu T, Chen G. Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients. Int J Mol Sci. 2013. 14(6): 11145-56.
[10] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009. 45(2): 228-47.
[11] MOORE BW, MCGREGOR D. CHROMATOGRAPHIC AND ELECTROPHORETIC FRACTIONATION OF SOLUBLE PROTEINS OF BRAIN AND LIVER. J Biol Chem. 1965. 240: 1647-53.
[12] Viallard JL, Tiget F, Hartmann O, et al. Serum neuron-specific/nonneuronal enolase ratio in the diagnosis of neuroblastomas. Cancer. 1988. 62(12): 2546-53.
[13] Jørgensen LG, Hansen HH, Cooper EH. Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol. 1989. 25(1): 123-8.
[14] Yesner R, Carter D. Pathology of carcinoma of the lung. Changing patterns. Clin Chest Med. 1982. 3(2): 257-89.
[15] Noone AM HN, M,etal K. SEER Cancer Statistics Review,
1975-2015. Based on the November 2017
SEER data submission. National Cancer Institute, 2018. seer.cancer.
gov/csr/1975_2015/. .
[16] Minari R, Bordi P, Del Re M, et al. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer. 2018. 115: 21-27.
[17] Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011. 3(75): 75ra26.
[18] Li S, Cao L, Wang X, Wang F, Wang L, Jiang R. Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements. Med Sci Monit. 2019. 25: 675-690.
[19] Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer. 2003. 41(3): 311-20.
[20] van Zandwijk N, Jassem E, Bonfrer JM, Mooi WJ, van Tinteren H. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol. 1992. 19(1 Suppl 2): 37-43.
[21] Diez M, Torres A, Ortega L, et al. Value of serum neuron-specific enolase in nonsmall cell lung cancer. Oncology. 1993. 50(2): 127-31.
[22] Suh KJ, Keam B, Kim M, et al. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. Clin Lung Cancer. 2016. 17(4): 245-252.e1.
[23] Fiala O, Pesek M, Finek J, et al. The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected]. Anticancer Res. 2014. 34(9): 5193-8.
[24] Wang Y, Tang D, Sui A, et al. Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib. Clin Transl Oncol. 2013. 15(5): 384-90.
[25] Petrović M, Baskić D, Banković D, Ilić N. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer. Biomarkers. 2011. 16(4): 311-20.
[26] Gazdar AF, Kadoyama C, Venzon D, et al. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr. 1992. (13): 191-6.
[27] Berendsen HH, de Leij L, Poppema S, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol. 1989. 7(11): 1614-20.
[28] Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007. 63(1): 12-31.
[29] Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer. 2003. 97(10): 2487-97.
[30] Hage R, Elbers HR, Brutel de la Rivière A, van den Bosch JM. Neural cell adhesion molecule expression: prognosis in 889 patients with resected non-small cell lung cancer. Chest. 1998. 114(5): 1316-20.
[31] Jacot W, Quantin X, Boher JM, et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer. 2001. 84(7): 903-9.